Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations.

@article{Nakada2006EarlyGC,
  title={Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations.},
  author={S. Nakada and Y. Katsuki and I. Imoto and T. Yokoyama and M. Nagasawa and J. Inazawa and S. Mizutani},
  journal={The Journal of clinical investigation},
  year={2006},
  volume={116 1},
  pages={
          80-9
        }
}
  • S. Nakada, Y. Katsuki, +4 authors S. Mizutani
  • Published 2006
  • Biology, Medicine
  • The Journal of clinical investigation
    • Topoisomerase II (Topo II) inhibitors are cell cycle-specific DNA-damaging agents and often correlate with secondary leukemia with chromosomal translocations involving the mixed-lineage leukemia/myeloid lymphoid leukemia (MLL) gene on chromosome 11 band q23 (11q23). In spite of the clinical importance, the molecular mechanism for this chromosomal translocation has yet to be elucidated. In this study, we employed 2-color FISH and detected intracellular chromosomal translocations induced by… CONTINUE READING
    View PDF
    47 Citations
    Highly Influencial Citations
    4
    Background Citations
    22
    Methods Citations
    1
    Results Citations
    1
    47 Citations
    Citation Type

    Citation Type

    Etoposide and illegitimate DNA double-strand break repair in the generation of MLL translocations: new insights and new questions.
    • 54
    Dysregulation of the DNA Damage Response and KMT2A Rearrangement in Fetal Liver Hematopoietic Cells
    • 7
    • PDF
    Dietary flavonoids induce MLL translocations in primary human CD34+ cells.
    • 99
    • PDF
    Differential cell cycle-specificity for chromosomal damage induced by merbarone and etoposide in V79 cells.
    • 20
    The effects of anti-DNA topoisomerase II drugs, etoposide and ellipticine, are modified in root meristem cells of Allium cepa by MG132, an inhibitor of 26S proteasomes.
    • 3
    Synergism between Etoposide and 17-AAG in Leukemia Cells: Critical Roles for Hsp90, FLT3, Topoisomerase II, Chk1, and Rad51
    • 53
    • PDF
    ATM Modulates the Loading of Recombination Proteins onto a Chromosomal Translocation Breakpoint Hotspot
    • 16
    • PDF
    Title Distinct roles of ATM and ATR in the regulation of ARP 8 phosphorylation to prevent chromosome translocations
    • Highly Influenced
    • PDF
    CBL mutation in childhood therapy-related leukemia
    • 5
    • PDF
    TACC3 deregulates the DNA damage response and confers sensitivity to radiation and PARP inhibition
    • 19

    References

    SHOWING 1-10 OF 53 REFERENCES
    DNA topoisomerase II in therapy-related acute promyelocytic leukemia.
    • 243
    Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors.
    • 166
    • PDF
    International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy‐related myelodysplastic syndromes and acute leukemia: Overview report
    • 180
    Topoisomerase-specific drug sensitivity in relation to cell cycle progression.
    • 152
    • PDF
    Leukemias related to treatment with DNA topoisomerase II inhibitors.
    • C. Felix
    • Biology, Medicine
    • Medical and pediatric oncology
    • 2001
    • 171
    Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer.
    • 124
    Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement.
    • 39
    • PDF
    Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): A report from the Children's Cancer Group
    • 163
    Topoisomerase II·Etoposide Interactions Direct the Formation of Drug-induced Enzyme-DNA Cleavage Complexes*
    • 123
    • PDF
    Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites.
    • 243
    • PDF